Screener
Ionis Pharmaceuticals IONS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Amortization of debt issuance costs | 4,150 | 3,288 |
| Non-cash royalty revenue related to sale of royalties | (22,387) | (24,894) |
| Non-cash interest related to sale of future royalties | 34,538 | 37,165 |
| Stock-based compensation expense | 88,870 | 59,408 |
| Loss (gain) on investments, net | (12,401) | 20,471 |
| Non-cash losses related to other assets | 481 | 297 |
| Changes in operating assets and liabilities: | ||
| Contracts receivable | 7,214 | 39,608 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's stock-based comp?
- Ionis Pharmaceuticals (IONS) reported stock-based comp of $45.6M in Q2 2026.
- How has Ionis Pharmaceuticals's stock-based comp changed year-over-year?
- Ionis Pharmaceuticals's stock-based comp increased by 53.6% year-over-year, from $29.69M to $45.6M.
- What is the long-term trend for Ionis Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's stock-based comp has grown at a 2.6% compound annual growth rate (CAGR), from $120.68M to $133.87M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Ionis Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude